Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Year
Author
Title
Keywords
Recent Submissions
FAQ
Top 10 Submissions
Top 10 SumSU Authors
Statistics
Help
Sign on
My DSpace
Receive email
updates
Edit Profile
SumDU Repository
Browsing by Author Bondarenko, I.
Showing results 1 to 5 of 5
Issue Year
Title
Author(s)
Type
Views
Downloads
2022
Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Felip, E.
;
Altorki, N.K.
;
Zhou, C.
;
Vallieres, E.
;
Vynnychenko, Ihor Oleksandrovych
;
Akopov, A.
;
Martinez-Marti, A.
;
Chella, A.
;
Bondarenko, I.
;
Ursol, G.
;
Levchenko, E.
;
Kislov, N.
;
Liersch, R.
;
Belleli, R.
;
McNally, V.A.
;
Bennett, E.
;
Gitlitz, B.J.
;
Wakelee, H.
Conference Papers
4009127
5569260
2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Shah, M.A.
;
Udrea, A.A.
;
Bondarenko, I.
;
Mansoor, W.
;
Sánchez, R.G.
;
Sarosiek, T.
;
Bozzarelli, S.
;
Schenker, M.
;
Gomez-Martin, C.
;
Morgan, C.
;
Özgüroğlu, M.
;
Pikiel, J.
;
Kalofonos, H.P.
;
Wojcik, E.
;
Buchler, T.
;
Swinson, D.
;
Cicin, I.
;
Joseph, M.
;
Vynnychenko, Ihor Oleksandrovych
;
Luft, A.V.
;
Enzinger, P.C.
;
Salek, T.
;
Papandreou, C.
;
Tournigand, C.
;
Maiello, E.
;
Wei, R.
;
Ferry, D.
;
Gao, L.
;
Oliveira, J.M.
;
Ajani, J.A.
Article
413609
56480
2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U.
;
Türeci, Ö.
;
Manikhas, G.
;
Lordick, F.
;
Rusyn, A.
;
Vynnychenko, Ihor Oleksandrovych
;
Dudov, A.
;
Bazin, I.
;
Bondarenko, I.
;
Melichar, B.
;
Dhaene, K.
;
Wiechen, K.
;
Huber, C.
;
Maurus, D.
;
Arozullah, A.
;
Park, J. W.
;
Schuler, M.
;
Al-Batran, S.-E.
Article
1
0
2021
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Rugo, H.S.
;
Pennella, E.J.
;
Gopalakrishnan, U.
;
Hernandez‑Bronchud, M.
;
Herson, J.
;
Koch, H.F.
;
Loganathan, S.
;
Deodhar, S.
;
Marwah, A.
;
Manikhas, A.
;
Bondarenko, I.
;
Mukhametshina, G.
;
Nemsadze, G.
;
Parra, J.D.
;
Abesamis‑Tiambeng, M.L.T.
;
Baramidze, K.
;
Akewanlop, C.
;
Vynnychenko, Ihor Oleksandrovych
;
Sriuranpong, V.
;
Mamillapalli, G.
;
Roy, S.
;
Ruiz, E.P.Ya.
;
Barve, A.
;
Fuentes‑Alburo, A.
;
Walle, C.F.
Article
0
0
2021
Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Gafanov, R.
;
Powles, T.B.
;
Bedke, J.
;
Stus, V.
;
Waddell, T.S.
;
Nosov, D.
;
Pouliot, F.
;
Soulieres, D.
;
Melichar, B.
;
Azevedo, S.
;
McDermott, R.S.
;
Vynnychenko, Ihor Oleksandrovych
;
Borchiellini, D.
;
Markus, M.
;
Bondarenko, I.
;
Lin, J.
;
Burgents, J.
;
Molife, L.R.
;
Plimack, E.R.
;
Rini, B.
Conference Papers
13882134
17079006
Current filters:
×
Sort by:
issue year
title
submit date
In order:
Ascending
Descending
Results/Page
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Jump to a point in the index: